PRIZE APPLICATION TEMPLATE

Application (Part B)

Version 1

27 April 2016

Disclaimer:

This document is aimed at informing potential contestants for the Horizon Birth Day Prize. It serves only as an example. The actual web forms and templates, provided in the online submission system

Under the Participant Portal, might differ from this example. Applications must be prepared and submitted via the online submission system

PRIZE APPLICATION TEMPLATE
Application (Part B)

Please follow the structure of this template when preparing your application. It has been designed to ensure that the important aspects of your work are presented in a way that will enable the experts to make an effective assessment against the evaluation criteria.

Page limits:

The entire part B should not be longer than 70 pages (if your application is positively evaluated, you might be asked to provide additional documentation in a hearing).

All tables in these sections must be included within this limit. The minimum font size allowed is 11 points. The page size is A4, and all margins (top, bottom, left, right) should be at least 15 mm (not including any footers or headers).

If you attempt to upload an application longer than the specified limit, you will receive an automatic warning, and will be advised to shorten and re-upload the application. After submission, any excess pages will be overprinted with a 'watermark', indicating to evaluators that these pages must be disregarded.

Please respect the page limit and do not take it as a target either! It is in your interest to keep your text as concise as possible, since experts rarely view unnecessarily long applications in a positive light.

COVER PAGE

Title of application:

List of contestant(s)

Contestant No *	Contestant organization name	Country
1 (Coordinator)		
2		
3		

* Please use the same contestant numbering as that used in the administrative application forms.

Table of Contents

1. ABSTRACT

2. INTRODUCTION

Concept and approach

Describe and explain the overall concept underpinning the proposed solution. Describe main ideas, models or assumptions involved. Identify any trans-disciplinary considerations.

3. DETAILED DESCRIPTION OF THE PROPOSED SOLUTION

Describe the proposed solution in detail specifically addressing each of the Award Criteria set out in the Rules of Contest (see also below).

The prize will be awarded to the application that in the opinion of the jury demonstrates a solution that best addresses the following cumulative criteria:

(a) Demonstrated (through scientifically sound and well-established methods) reduction of maternal and/or new-born morbidity and mortality and/or number of stillbirths in facility-based deliveries. The main focus of the Birth Day Prize is improving outcome of a facility based delivery.

(b) Absence of clear safety concerns (also with respect to the potential effect in the longer term – no adverse effects) documented over a period of at least six months

(c) Potential for rapid scalability, demonstrated by the affordability, acceptability and simplicity in use of the proposed application.

A. Reduction of maternal and/or newborn mortality/morbidity and/or stillbirths: The contestants will have to provide evidence on the positive impact of the submitted application on the health outcomes in the intervention facility(-ies). The evidence should highlight how the application has improved the health outcomes in terms of mortality and/or morbidity of mothers and/or newborns and/or stillbirths. The main focus of the Birth Day Prize is on delivery and the neonatal period (i.e. 28 days after birth); the outcomes measures of submitted applications should thus specifically address this period of time.

As far as morbidity is concerned, a greater value will be placed on applications that address conditions that represent a high risk to the individual or a high volume or a high cost to the health system and society.

A greater value will be placed on applications that have demonstrated an impact on the health outcomes of mothers AND newborns AND stillbirths (including mortality and morbidity, if possible).

Method of measurement: health outcomes from the facility (-ies) covered by the application compared to baseline assessment; scientific arguments supporting the attribution of the reduction of maternal and/or newborn mortality/morbidity and/or stillbirths to the application.

- **With respect to the scientifically sound methodology**: contestants will have to provide data on the process underpinning the application. The contestants should provide a clear methods section with a description of measurements, tools for measurement, reasons for choosing tools, justification/rationale for choice of a particular site or sites for the pilot or intervention and - if relevant – description of sample and reasons for sample choice.

  Method of measurement: Quality and effectiveness of the S/T (Scientific and or Technological) methodology, used to describe the evidence, reliability of the data provided.

- **With respect to the Innovative aspect:** the application has to be novel and developed by the contestant. The novelty of the application can be either in the application itself or in the way it is being implemented (i.e. an already existing application that is being used in a novel manner, i.e. in a different context or at scale)

  Method of measurement: the extent to which the application is beyond the state of the art, and demonstrates innovation (e.g. novel concepts and approaches, new products, services or business and organisational models).

B. Absence of safety concerns. Contestants will include a risk-benefit analysis with a Risk intensity rating (low, medium high) and a Risk Management Plan for the medium to high identified risks of the application over a period of minimum 6 months.

Method of measurement: data on all potential adverse effects identified within the application and how each of them has been addressed, quality of the risk management plan.

Concerning medicinal products-related applications, the evidence will depend on the actual status of the products used. If these are still in trial, the contestant will provide copies of approval from national authorities and/or opinion of the ethical committees for the relevant clinical trials. For applications using medicinal products that have already been approved, the contestant will provide information on the regulation status of the products in this or other indication.

Important remark: applications showing clear safety concerns will not be considered for being awarded any of the prizes. In this view, the threshold and maximum points are identical: applications receive a score of 0 if clear safety concerns emerge from the evaluation or a score of 10 if no clear safety concerns arise.

C. Potential for rapid scalability. Contestants will have to provide data and/or arguments to defend the scalability of their proposed application. The application should thus be reproducible in settings of intended use. Supporting documentation can be real data on the implementation of the application in different settings or scientific arguments supporting the applicability of the application in settings of intended use.

A greater value will be placed on applications that have demonstrated their replicability in settings of intended use as opposed to those who only argue they are replicable. Should the application include (a) product (s) that is (are) intended to go to market, research data on the unmet need as well as a competitive situational analysis – both of which can either help or hinder market uptake should be included.

Method of measurement: data on the actual implementation of the application in different settings (if available) or scientific arguments supporting the replicability of the application in various settings of intended use.

- **with respect to affordability:** the contestants should provide evidence of how the application could be economically viable for the setting(s) in which it is intended.

  Method of measurement: description of the costs associated with building the application (Cost of Goods), description of the costs associated with the implementation of the application (including consumables, required ancillary items); an estimate of the cost-benefit of the application.

- **With respect to acceptability:** the application should be acceptable to end-users, health providers and payers from the setting(s) in which the application is intended. The contestants will provide data from research supporting the acceptability of the application or provide evidence or sound assumption-based arguments that the application will likely be acceptable to the population and the health providers of the setting.

Method of measurement: research data on an actual end-user (and other users if applicable) and health professional acceptability in the intended facility (-ies) or evidence or sound assumption-based scientific arguments supporting the acceptability of the application for end-users and/or health professionals in the intended facility (-ies). Acceptability includes willingness to accept a unique application and/or replace a proven application with a new one.

- **With respect to simplicity in use**: the application should be usable by facility-based health workers within the setting(s) in which it is intended. Simplicity in use and re-use and limited need for training are preferred.

  Method of measurement: evidence that health workers of the facility have the necessary knowledge and training to use the application, a list of the necessary knowledge and training necessary to use the application in a satisfactory manner